Abstracts tagged "TNF-α blockers and Drug efficacy"

Abstract Number: 1966 • 2019 ACR/ARP Annual Meeting
A Genome-Wide Association Study of Copy Number Variations Identifies the Deletion Associated with Efficacy of TNF-Alpha Blocker Therapy in Korean Patients with Rheumatoid Arthritis
Ki-Nam Gu ¹, So-Young Bang², Hye-Soon Lee ³, Youngho Park ², Juyeon Kang ², Ji-Soong Kim ², Bora Nam ², Hyun-Seung Yoo ⁴, Jung-Min Shin ², Yeon-Kyung Lee ², Tae-Han Lee ², Sehwan Chun ¹, Soo-Kyung Cho ², Chan-Bum Choi ², Yoon-Kyoung Sung ⁵, Tae-Hwan Kim ², Jae-Bum Jun ², DaeHyun Yoo ², Kwangwoo Kim ¹ and Sang-Cheol Bae ², ¹Kyung Hee University, Seoul, Republic of Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Department of Internal Medicine, Hanyang University Guri Hospital,Hanyang University School of Medicine, Guri, Korea, Guri, Republic of Korea, ⁴Hanyang University Hospital, Guri, Republic of Korea, ⁵Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Copy number variation (CNV) is the most common structural variation defined as large ( >1 kb) genomic deletions and duplications and could yield a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].